tbuckley/cabot-search huggingface dataset:
183 SINGLE OPERATOR PERORAL CHOLANGIOSCOPY IN LIVER TRANSPLANT RECIPIENTS REQUIRING EVALUATION OF THE BILIARY TRACT
Authors: D. Balderramo, O. Sendino, J.M. Bordas, G. Martinez-Palli, C. Rodriguez de Miguel, R. Miquel, M. Navasa, J. Llach, A. Cardenas
Journal: Journal of Hepatology (2012)
Case 23-2014
Authors: Christine M. Hay, Jo-Anne O. Shepard, Emily P. Hyle, Lyn M. Duncan
Journal: New England Journal of Medicine (2014)

A 41-year-old man was admitted to the hospital in midsummer because of fever, rash, pancytopenia, and abnormal results of liver-function tests. Two days before the onset of fever, he had returned from a 3-week trip to Europe. Diagnostic tests were performed.
Abstract 4878: The fallopian tube is the origin of high-grade serous ovarian carcinomas in a mouse model
Authors: Jaeyeon Kim, Donna M. Coffey, Chad J. Creighton, Zhifeng Yu, Shannon M. Hawkins, Martin M. Matzuk
Journal: Cancer Research (2012)

Abstract Ovarian cancer is a lethal disease primarily because it is often not detected until it spreads beyond the female reproductive tract. Early detection is thus the key to successful intervention in ovarian cancer. Yet it is not known how this cancer arises and metastasizes. In the last decade, new evidence has challenged the dogma that the ovary is the main source of these cancers. The fallopian tube has been proposed instead as the primary origin of high-grade serous ovarian cancer _ the subtype causing 70% of ovarian cancer deaths. To understand the origin and early progression of this serous cancer, we have generated double knockout (DKO) mice by conditionally disabling in the reproductive tract two critical genes _ Dicer, an essential gene for microRNA synthesis, and Pten, a tumor suppressor that negatively regulates the PI3K pathway. These DKO mice develop high-grade serous carcinomas that arise from the fallopian tube. These high-grade serous cancers spread to engulf the ovary and then extensively metastasize throughout the abdominal cavity, causing ascites and killing 100% of the mice by 13 months. This is the first mouse model demonstrating that the fallopian tube is capable of initiating and developing high-grade serous carcinomas with similar clinical manifestations shown in the human serous ovarian carcinomas. Intriguingly, analyzing these DKO tumors at early time points also reveals that these epithelial cancers begin in the stroma of the fallopian tube, suggesting that the cancers arise through a mesenchymal-to-epithelial transition (MET) _ a novel mechanism of carcinoma initiation. This study thus presents a new paradigm for the origin and initiation of deadly high-grade serous ovarian cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4878. doi:1538-7445.AM2012-4878
Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer
Authors: Xin Chen, Qiuhui Li, Xin Liu, Can Liu, Ruifang Liu, Kiera Rycaj, Dingxiao Zhang, Bigang Liu, Collene Jeter, Tammy Calhoun-Davis, Kevin Lin, Yue Lu, Hsueh-Ping Chao, Jianjun Shen, Dean G. Tang
Journal: Clinical Cancer Research (2016)

Abstract Purpose: We have shown that the phenotypically undifferentiated (PSA−/lo) prostate cancer cell population harbors long-term self-renewing cancer stem cells (CSC) that resist castration, and a subset of the cells within the PSA−/lo population bearing the ALDHhiCD44+α2β1+ phenotype (Triple Marker+/TM+) is capable of robustly initiating xenograft tumors in castrated mice. The goal of the current project is to further characterize the biologic properties of TM+ prostate cancer cell population, particularly in the context of initiating and propagating castration-resistant prostate cancer (CRPC). Experimental Design: The in vivo CSC activities were measured by limiting-dilution serial tumor transplantation assays in both androgen-dependent and androgen-independent prostate cancer xenograft models. In vitro clonal, clonogenic, and sphere-formation assays were conducted in cells purified from xenograft and patient tumors. qPCR, Western blot, lentiviral-mediated gene knockdown, and human microRNA arrays were performed for mechanistic studies. Results: By focusing on the LAPC9 model, we show that the TM+ cells are CSCs with both tumor-initiating and tumor-propagating abilities for CRPC. Moreover, primary patient samples have TM+ cells, which possess CSC activities in “castrated” culture conditions. Mechanistically, we find that (i) the phenotypic markers are causally involved in CRPC development; (ii) the TM+ cells preferentially express castration resistance and stem cell–associated molecules that regulate their CSC characteristics; and (iii) the TM+ cells possess distinct microRNA expression profiles and miR-499-5p functions as an oncomir. Conclusions: Our results define the TM+ prostate cancer cells as a population of preexistent stem-like cancer cells that can both mediate and propagate CRPC and highlight the TM+ cell population as a therapeutic target. Clin Cancer Res; 22(17); 4505–16. ©2016 AACR.
Abstract 402: Role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in chemotherapy induced myeloid leukemia
Authors: Ratnakar Potla, Anil K. Jaiswal
Journal: Cancer Research (2010)

Abstract Individuals with NQO1P187S mutation have no detectable NQO1 protein levels. These individuals have been extensively predicted to be at high risk for developing chemotherapy-induced leukemia. We have studied the effect of Etoposide, a DNA Topoisomerase II inhibitor used in many chemotherapeutic regimens, on NQO1 gene deleted (NQO1-/-) mice. NQO1-/- mice are born with a myelodysplastic bone marrow. Flow cytometric analysis of blood, bone marrow and spleen showed an increase in megakaryocytic and myeloid cell lineages in NQO1-/- mice. A spectrum of responses ranging from leukopenia to myeloid leukemia were observed with increasing drug concentration by Flow cytometry and confirmed by histochemistry in NQO1-/- mice. C/EBPalpha plays a key role in the myeloid lineage commitment of hematopoietic progenitor cells. NQO1 protects C/EBPalpha from 20S proteasomal degradation in in vitro assays. Altered C/EBPalpha levels are responsible for the preferential increase in myeloid cell lineage in NQO1-/- mice. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 402.
Abstract LB-403: Recurrent fusion transcripts in breast cancer
Authors: Anguraj Sadanandam, Stephan Wullschleger, Paul Spellman, Douglas Hanahan, Joe W. Gray
Journal: Cancer Research (2012)

Abstract Breast cancer is the second leading cause of cancer deaths among women in the United States. Genome wide analyses in primary breast tumors and ∼50 breast cancer cell lines using gene expression profiling revealed subsets defined as luminal, basal-like, ERBB2 and claudin-low. The general hypothesis is that recurrent fusion transcripts exist and play a central role in the pathophysiology and clinical outcome of breast cancer. We identified recurrent fusion transcripts specific to breast cancer cell lines by performing Solexa based paired-end sequencing of whole-transcriptome (RNAseq) using 9 basal, 9 luminals, 4 ERBB2 and 1 claudin-low breast cancer cell lines. In addition, we cross-compared the predicted fusion transcripts with that of copy number and gene expression changes in the respective cell lines and performed gene ontology (GO) based enrichment analysis using the genes that were involved in the fusion. The sequencing of 19 breast cancer cell lines resulted in a range of ∼15 million to ∼45 million paired-end reads of 76 bp per cell line and out of which 93% to 98.6% had quality reads. On average, we predicted ∼14 fusion genes per cell lines (331 fusion genes in total) that are expressed atleast in one cell line. Interestingly, basal breast cancer cell lines on average have more number of fusion transcripts (∼13 per cell line and 115 in total) whereas luminal cell lines have only ∼9 predicted fusion transcripts per cell line (84 in total). Among the 418 unique genes that were involved in fusion processes, 20% of the genes occurred atleast twice and GO enrichment analysis show similar terms to be significantly enriched. Intriguingly, we identified 24 different recurrent fusion transcripts in total. In summary, the data demonstrates that there is more number of predicted fusion transcripts in breast cancer than initially thought. Also, the data suggest that genes with similar functions or processes fuse together. Currently studies are in progress to test if recurrent gene fusions may have a functional role, which may assist in the design of appropriate strategies to target recurrent events, and may be associated with poor outcome of basal breast cancers. Overall, this may improve the prognosis of breast cancer patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-403. doi:1538-7445.AM2012-LB-403
AB0616 Risk assessment of falls in patients with osteoporosis and rheumatoid arthritis
Authors: L. Myasoutova, A. Vasiliev, S. Lapshina
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> Assess the risk of falls in patients with osteoporosis (OP) and rheumatoid arthritis (RA) <h3>Methods</h3> Complete clinical-epidemiological evaluation of 72 patients with a documented diagnosis of RA (according to the criteria of ACR, 1987.) and OP [women - 54 (75%), men - 18 (25%), mean age - 55,7 ± 8,6 years, duration of RA - 7,4 ± 5,3 years] was performed. Patients were asked to report the number of drops from its own growth made to them within 1 year prior to this study, and the number of fractures due to falls. Osteoporotic fractures (at least one fracture, stratification “yes / no“) of the proximal femur, tibia bone, forearm, upper arm were described. Also, all patients were assessed functional status by index HAQ. <h3>Results</h3> 15 patients (20.8%) reported that they had not a single drop, and 21 (29.2%) - fell 1 time, 27 (37.5%) - 2 times, 9 (12.5%) - 3 times or more. Most of the falls (65.8%) occurred in the winter. At least one osteoporotic fracture occurred in 23 (31.9%) patients, 12 (52.2%) of these fractures were repeated and in 16 (69.6%) occurred as a result of two or more falls. It was also established that the degree of restriction of the functional status (HAQ) and the number of falls there is a direct correlation (ρ = 0,23; p &lt;0,05). <h3>Conclusions</h3> Fall - an independent risk factor for osteoporotic fractures. In RA the risk of falls is quite high, largely due to decreased functional status of patients. It is shown that fractures often occur as a result of repeated falls, and therefore must be a set of measures aimed at reducing the impact of potential risk factors for falls, including the improvement of the functional status of patients. <h3>Disclosure of Interest</h3> None Declared
PROGNOSTIC UTILITY OF LEFT VENTRICULAR MASS INDEX MEASURED BY CMR IN PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE
Authors: Ahmed Abdi Ali, Robert Miller, Danielle Southern, Mei Zhang, Yoko Mikami, Heydari Bobak, Andrew Howarth, Carmen Lydell, Matthew James, Stephen Wilton, Merril Knudtson, James White
Journal: Journal of the American College of Cardiology (2016)
In Situ Characterization of Autoimmune Phenomena and Expression of HLA Molecules in the Pancreas in Diabetic Insulitis
Authors: Gian Franco Bottazzo, Betty M. Dean, Jessica M. McNally, E. Hugh MacKay, Peter G.F. Swift, D. Robert Gamble
Journal: New England Journal of Medicine (1985)

After the death of a 12-year old girl with newly discovered insulin-dependent diabetes mellitus, we used monoclonal antibodies in an effort to identify the cells invading the pancreas. The majority of infiltrating lymphocytes were of the T cytotoxic/suppressor phenotype, but other T-cell subpopulations were present. Some of the T cells were "activated" (positive for HLA-DR antigen, and the interleukin-2 receptor). Immunocytes bearing IgG were scattered in the gland, and complement-fixing IgG antibodies were deposited in some islets. Increased expression of Class I (HLA-A, B, and C) molecules was observed in the affected islet cells, and in damaged islets showing scant lymphocytic infiltration, some beta cells (still producing insulin), but not glucagon or somatostatin cells, were HLA-DR positive. The capillary endothelium was markedly dilated and strongly HLA-DR positive. These findings may contribute to an understanding of the sequence of events leading to the destruction of beta cells in classic Type I diabetes mellitus. (N Engl J Med 1985; 313:353)
Usefulness and limitations of taste sensors in the evaluation of palatability and taste-masking in oral dosage forms
Authors: Tamami Haraguchi, Miyako Yoshida, Honami Kojima, Takahiro Uchida
Journal: Asian Journal of Pharmaceutical Sciences (2016)

The purpose of this review is to discuss the advantages and limitations of taste sensors in the evaluation of the taste of palatability of different oral dosage forms. First, we consider some ways in which the palatability of various pharmaceutical formulations including orally disintegrating tablets (ODTs) are tested using two different taste sensors. Second, we focus on the evaluation of palatability of ODTs. We compare the usefulness of three pieces of apparatus for estimating the disintegration time of ODTs. Finally, we compare the characteristics of the two taste sensors in the evaluation of palatability of various kinds of drug formulations.
Abstract 307: Acquisition of the invasive phenotype and EMT profile by CXCL7 transfection
Authors: Mary A. Kosir, Donghong Ju
Journal: Cancer Research (2012)

Abstract Introduction: The expression of CXCL7 is associated with the invasive phenotype through interaction with the CXCL7/CXCR2 axis and heparan sulfate. A component of the epithelial to mesenchymal transition (EMT) is degradation of extracellular matrix and acquisition of migration, both of which support invasiveness. The purpose of this study is to quantify the expression of genes associated with EMT by CXCL7-expressing cells with the invasive phenotype. Methods: Total RNA from CXCL7-transfected breast cells (MCF10AT) was tested for relative gene expression using RT2 ProfilerTM PCR array for EMT (SABiosciences). Vector transfected cells were compared. Each result was verified by real time PCR assay. Results: The expression of GNG11 and TCF4 was upregulated and SPP1 downregulated as expected for the EMT profile. Specifically, GNG11 (Guanine nucleotide binding protein (G protein), gamma 11) expression was increased 2.94 fold and TCF4 (Transcription factor 4) increased 1.89 fold. The expression of SPP1 (Secreted phosphoprotein 1) was decreased by 6.8 fold. The expression of ZEB2 (Zinc finger E-box binding homeobox 2) was decreased by 1.96 as a transcription factor. Summary: The CXCL7-transfected cells with invasive phenotype express genes associated with the EMT expression profile including G-protein signaling pathway. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 307. doi:1538-7445.AM2012-307
AB0280 Imnunogenicity and clinical practice in patients treated with anti-tnf therapy
Authors: P. Alcocer, C. Plasencia, D. Pascual, S. Garcia Carazo, K. N. Franco, D. Cagijas, L. Lojo, G. Bonilla, L. Nuño, A. Villalba, M. T. López Casla, A. Balsa, E. Martín Mola
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Biological therapy (BT) is very effective in patients with rheumatoid arthritis (RA). Although there are tools to measure treatment response, they have limitations making necessary to get more objective parameters to improve clinical evaluation. The immunogenicity of anti-TNF therapy has been associated with lack of efficacy, side effects and decreased survival. In our hospital, the monitoring of immunogenicity is considered as an additional tool to clinical practice since 2010, helping in treatment decisions as switching medication, dose reduction or even discontinuation. <h3>Objectives</h3> To asses the benefit of using the immunogenicity as a complementary tool in clinical practice of RA patients and to analyse differences in outcome measures before and after the use of immunogenicity. <h3>Methods</h3> We included 134 RA patients who started a 1st biologicbetween the years 2005-2012. The patients were divided into two time periods to analyze differences in clinical management after to monitor the BT immunogenicity: 1st period (1P) from 2005 to 2009 with 89 patients and 2nd period (2P) from 2010 to 2012 with 45 patients. The used drugs were infliximab, adalimumab, etanercept, rituximab, tocilizumab, abatacept and certolizumab. The clinical activity was measured by DAS28 and the clinical improvemet by delta-DAS28. The drug and anti-drug antibodies (ADA) serum levels were measured by ELISA. Statistical analysis was performed using SPSS 11.0. <h3>Results</h3> A similar control of disease activity is achieved in both periods, but in the 2P, where in addition to the usual measures we use immunogenicity monitoring, shows that we are more cost-effective, taking decisions earlier and more accurate. These data suggest that immunogenicity can help to improve and personalize the clinical manage of patients treated with biologicals. <h3>Conclusions</h3> A similar control of disease activity is achieved in both periods, but in the 2P, where in addition to the usual measures we use immunogenicity monitoring, shows that we are more cost-effective, taking decisions earlier and more accurate. These data suggest that immunogenicity can help to improve and personalize the clinical manage of patients treated with biologicals. <h3>Disclosure of Interest</h3> None Declared
FRI0015 Understanding between Physician and Patient with Rheumatoid Arthritis as a Tool for Effective Therapy (T2T Connect Implementation)
Authors: L. Myasoutova, S. Lapshina, R. Mukhina, M. Aphanasieva, M. Sadykov
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Understanding between physician and patient with rheumatoid arthritis as a tool for effective therapy (T2T connect implementation). <h3>Objectives</h3> To identify the most significant problems for patient in disease understanding in order to create a system of effective physician-patient with RA interaction in future. <h3>Methods</h3> 40 patients with confirmed RA, (mean duration of the disease 4,6 years, the average age of patients - 56.8 years) responded to 10 questions of the questionnaire concerning their relationship to the disease and the impact on the daily life with the need to evaluate the importance of each question on a scale from 1 to 10. Doctors rheumatologists (n=10) and physicians (n=30) answered the same questions from the position what they think is important for patients. Responses were ranked and compared. <h3>Results</h3> The most important issues for patients were - constant need for prolonged therapy and side effects of therapy, third place - future prognosis and understanding the causes of disease. Next important question for patients was to determine the fear of constant pain. Doctors believed that patients are more concerned about the restriction in daily life because of the disease (patients raised this issue only in 6 out of 10). Further, according to the doctors opinion, patients worried about understanding of the causes of the disease (2) and predictions for the future (3). Next important question for patients, as doctors believed, was prolonged therapy (4), problems in personal and family life (5) and then persistant pain (6). <h3>Conclusions</h3> Understanding the patients view to their disease will allow to restructure the communication with the patient, to improve educational programs for them. In conversation with patient doctors must pay more attention to explanation of the need of long-term therapy and its safety. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5525
MICRORNA-21 UPREGULATION CONTRIBUTES TO RIGHT VENTRICULAR FAILURE THROUGH PHOSPHATASE AND TENSIN HOMOLOG-DRIVEN FIBROSIS
Authors: Jeffery Powers, Mitsuru Seki, John Holten, Anthony Poidomani, Dalia Al-Bataineh, Dhruv Chotalia, Lydia Kim, Abdelkarim Sabri, Fabio Recchia, Emily Tsai
Journal: Journal of the American College of Cardiology (2016)
LOW HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND INCIDENT CORONARY HEART DISEASE AMONG BLACKS IN THE REASONS FOR GEOGRAPHIC AND RACIAL DIFFERENCES IN STROKE (REGARDS) STUDY
Authors: Lisandro Colantonio, Sergio Fazio, Robert Rosenson, Michael Miller, Maciej Banach, Monika Safford, Paul Muntner, Peter Toth
Journal: Journal of the American College of Cardiology (2016)
Infarction of the Descending Colon Due to Vascular Occlusion
Authors: James J. McCort
Journal: New England Journal of Medicine (1960)

INFARCTION of the descending colon due to inferior mesenteric vascular occlusion alone and without mechanical obstruction such as volvulus or incarcerated hernia is uncommon. Exclusive of those mentioned as part of large series of mesenteric infarction, only 15 cases have been described in the available medical journals. During the past nine years, 3 patients with infarction of the descending colon due to occlusion of the inferior mesenteric artery have been seen. The clinical and radiologic findings in these cases were similar to those in others previously reported.IncidenceInfarction of the descending colon occurs much less frequently than that of . . .
Tc-99m LABELED MONOCLONAL ANTIBODIES FOR IMAGING METASTATIC DISEASE.
Authors: Janet F. Eary, Robert W. Schroff, Sudhakar Kasina, Alan R. Fritzberg, Alton C. Morgan, Kenneth A. Krohn, Clive Woodhouse, Paul G. Abrams, B. Wil
Journal: Clinical Nuclear Medicine (1986)

Eary, Janet F.; Schroff, Robert W.; Kasina, Sudhakar; Fritzberg, Alan R.; Morgan, Alton C. Jr.; Krohn, Kenneth A.; Woodhouse, Clive; Abrams, Paul G.; Wil, B. Author Information